Seattle Genetics, Inc. (SGEN): Price and Financial Metrics
Today's Latest Price: $192.34 USD
Oct 29 4:00pm Add SGEN to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
SGEN Stock Summary Seagen Inc's market capitalization of $33,903,241,407 is ahead of 94.38% of US-listed equities. With a one year PEG ratio of 841.94, Seagen Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 96.05% of US stocks. With a price/sales ratio of 33.38, Seagen Inc has a higher such ratio than 94.62% of stocks in our set. Stocks with similar financial metrics, market capitalization, and price volatility to Seagen Inc are BGNE, MRVL, EA, XLNX, and CDNS. SGEN's SEC filings can be seen here. And to visit Seagen Inc's official web site, go to www.seattlegenetics.com.
SGEN Price/Volume Stats
Seattle Genetics, Inc. (SGEN) Company Bio
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. The company was founded in 1998 and is based in Bothell, Washington.
SGEN Latest News Stream
All News Types
Commentary Corp. News Cramer Downgrade Earnings Guidance Down M&A New Coverage (Bearish) New Coverage (Bullish) New Coverage (Neutral) Options Product News PT Lowered PT Raised PT Set (Bearish) PT Set (Bullish) PT Set (Neutral) Rating Reiterated (Bearish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Resumes Coverage (Bullish) Resumes Coverage (Neutral) Stock Offering Upgrade
Loading, please wait...
Latest SGEN News From Around the Web
Below are the latest news stories about Seattle Genetics Inc that investors may wish to consider to help them evaluate SGEN as an investment opportunity.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Annexon Inc (NASDAQ: ANNX ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) CTI BioPharma Corp (NASDAQ: CTIC ) I-Mab ADR (NASDAQ: IMAB ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) (the blank check company announced a business combination with oncology-focused Vincera Pharma) Mirati Th...
The charts and indicators of SGEN are looking healthy….SGEN
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10X Genomics Inc (NASDAQ: TXG ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Beigene Ltd (NASDAQ: BGNE ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Evogene Ltd (NASDAQ: EVGN ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) InVitae Corp (NYSE: NVTA ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Incorporated (NASDAQ: PRLD ) (listed Thursday) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc...
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Patients had previously received a doublet chemotherapy and, if eligible, bevacizumab as fir
Genmab A/S (GMAB -1.3%) and development partner Seattle Genetics (SGEN -1.7%) announce positive results from a Phase 2 clinical trial, innovaTV 204, evalua
Read More 'SGEN' Stories Here
SGEN Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.8128 seconds.